{"id":"rld2001-2","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL299613","moleculeType":"Small molecule","molecularWeight":"302.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RLD2001-2 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"RLD2001-2 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:31.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04830449","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-29","conditions":"Hypertension","enrollment":122},{"nctId":"NCT05191563","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-07-31","conditions":"Healthy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RLD2001-2","genericName":"RLD2001-2","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RLD2001-2 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}